[ad_1]
The Oxford-AstraZeneca coronavirus vaccine, produced at the Serum Institute in India, received a green signal from a panel of experts to approve the vaccine, Reuters reported.
Experts from India’s Central Medicines Standards Control Organization (CDSCO) met on Friday to approve the approval, Reuters reported.
The matter will now be referred to the Office of the Comptroller General of Drugs (DCGI), India, for final approval. After that, to begin vaccinating citizens in January, the exercises will be held in all states of India on Saturday.
The UK approved the use of Covishield, an Oxford-AstraZeneca coronavirus vaccine, on December 30. Later, the vaccine was approved in Argentina.
According to NDTV, the approval of the relatively affordable Oxford vaccine is an important step forward for India. After the United States, India has the highest number of people infected with the coronavirus. In this country with the second largest population in the world, the number of identified patients has already exceeded a crore 2 lakh 8 thousand.
The Indian government plans to vaccinate 300 million people in India in the next six to eight months.
AstraZeneca says it will create three billion doses of vaccines for everyone in the next year. And in India, the Serum Institute of India has been involved in the production of this vaccine.
Adar Poonawala, executive director of the institute, said they had already prepared 50 million doses of the vaccine. They want to release at least 100 million doses by next March.
Three million crore of this vaccine will be provided in Bangladesh in January. The vaccine will be provided in Bangladesh by Beximco Pharmaceuticals Limited of the Serum Institute of India. Beximco has already announced plans to sell the vaccine commercially, as well as to the government of Bangladesh as an “exclusive distributor”.
[ad_2]
